Chronic myeloid leukaemia: open trials in France

30 open trials have a site in France. Registry data; only the trial team decides who can take part.

2026-525234-39-00
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Trial Treatment · Phase 1 · Janssen Cilag International
Institut Paoli-Calmettes, Marseille · Hospices Civils de Lyon, Pierre-Bénite · Oncopole Claudius Regaud, Toulouse · Centre Hospitalier Régional Universitaire de Tours, Tours
Registry updated 2026-11-06
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
Centre Hospitalier Universitaire de Lille, Lille · Institut Paoli-Calmettes, Marseille · Centre Hospitalier Universitaire de Nantes, Nantes · Institut Curie, Paris · Oncopole Claudius Regaud, Toulouse · Institut Gustave Roussy, Villejuif
Registry updated 2026-11-04
NCT06163430
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Trial Treatment · Phase 1/2 · Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Institut Bergonie, Bordeaux · Centre Leon Berard, Lyon · Institut Paoli-Calmettes, Marseille · Hospital Hotel Dieu, Nantes · Hopital Saint Louis, Paris · Centre Hospitalier Lyon-Sud, Pierre-Bénite
Registry updated 2026-10-15
NCT07354074
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Trial Treatment · Phase 2 · Novartis Pharmaceuticals
Marseille · Paris · Poitiers · Strasbourg
Registry updated 2026-10-15
NCT05130138
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia
Trial Treatment · Centre Hospitalier Universitaire de Saint Etienne
Chu de Saint Etienne, Saint-Etienne
Registry updated 2026-10-13
NCT03934372
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Trial Treatment · Phase 1/2 · Incyte Biosciences International Sàrl
Armand Trousseau Hospital, Paris · Hopital Robert Debre, Paris · Centre Hospitalier Universitaire de Poitiers, Poitiers · Chu de Rennes - Hospital Sud, Rennes
Registry updated 2026-10-09
NCT04256317
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Trial Treatment · Phase 2/3 · Taiho Oncology, Inc.
Centre Hospitalier Universitaire de Nice, Nice · Assistance Publique Hopitaux de Paris, Paris · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9
Registry updated 2026-10-06
2024-512503-39-00
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Trial Treatment · Phase 4 · Medizinische Hochschule Hannover
CHU Angers, ANGERS Cedex 09 · Centre Hospitalier Universitaire Grenoble Alpes, Grenoble Cedex 09 · Centre Hospitalier Universitaire de Nantes, Nantes · Centre Hospitalier Universitaire de Bordeaux, Pessac · Centre Hospitalier Universitaire De Rennes, Rennes Cedex 9 · Oncopole Claudius Regaud, Toulouse Cedex 9
Registry updated 2026-10-01
NCT07852494
Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia
Trial Treatment · Centre Hospitalier Universitaire de Nice
CHU de Nice, Nice
Registry updated 2026-10-01
NCT04925479
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Trial Treatment · Phase 1/2 · Novartis Pharmaceuticals
Bordeaux · Lille · Paris · Poitiers
Registry updated 2026-09-25
NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Trial Treatment · Phase 2 · Cogent Biosciences, Inc.
Necker-Enfants Malades Hospital, Paris · Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers · Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse
Registry updated 2026-09-15
NCT06423911
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Trial Treatment · Phase 3 · Ascentage Pharma Group Inc.
Centre Hospitalier Universitaire Amiens Picardie, Amiens Cedex 1 · Assistance Publique Hopitaux De Paris, Bobigny · Centre Hospitalier Universitaire de Nice, Nice · Centre Henri Becquerel, Rouen Cedex · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9
Registry updated 2026-09-15
NCT06439199
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
Research · Nantes University Hospital
Nantes University Hospital, Nantes
Registry updated 2026-09-09
2025-522138-29-00
Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
Trial Treatment · Phase 2 · Novartis Pharma AG
Centre Hospitalier Universitaire De Lille, Lille Cedex · Centre Hospitalier Regional De Marseille, Marseille · Robert Debre University Hospital, Paris · Centre Hospitalier Universitaire de Poitiers, Poitiers · Les Hopitaux Universitaires De Strasbourg, Strasbourg Cedex 2
Registry updated 2026-08-31
NCT07760311
Feasibility Study to Evaluate a Digital Tool for Monitoring Patients Who Have Discontinued Treatment for Chronic Myeloid Leukemia
Trial Treatment · Versailles Hospital
CH de Versailles, Le Chesnay
Registry updated 2026-08-12
NCT04093570
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Trial Treatment · Phase 2 · Taiho Oncology, Inc.
Hôpital Emile Muller, Mulhouse
Registry updated 2026-07-28
NCT07719348
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Trial Treatment · Phase 1/2 · Servier
Institut Paoli-Calmettes, Marseille · Centre Hospitalier Universitaire de Nice, Nice · Hopital Saint Louis, Paris · Centre Hospitalier Universitaire De Bordeaux, Pessac Cedex · Institut Gustave Roussy, Villejuif
Registry updated 2026-07-22
NCT02889003
Second STOP After Pioglitazone Priming in CML Patients
Trial Treatment · Phase 2 · Versailles Hospital
Centre Hospitalier de Versailles, Le Chesnay · Hopital Bicetre, Le Kremlin-Bicêtre · Chu Lyon, Lyon · CHU de Nantes, Nantes · CHU de Rennes, Rennes · IUCT, Toulouse
Registry updated 2026-07-06
NCT04877522
Asciminib Roll-over Study
Trial Treatment · Phase 4 · Novartis Pharmaceuticals
Institut Bergonie, Bordeaux · Centre Hospitalier Universitaire De Caen Normandie, Caen Cedex 9 · University Hospital Of Clermont-Ferrand, Clermont-Ferrand · Centre Hospitalier Universitaire de Lille, Lille · Centre Leon Berard, Lyon · Institut Paoli-Calmettes, Marseille · Centre Hospitalier Universitaire De Nantes, Nantes Cedex 1 · Centre Hospitalier Universitaire de Nice, Nice · Hopital Saint Louis, Paris · Centre Hospitalier Universitaire de Poitiers, Poitiers · Les Hopitaux Universitaires De Strasbourg, Strasbourg Cedex 2 · Oncopole Claudius Regaud, Toulouse · CHRU De Nancy, Vandoeuvre Les Nancy
Registry updated 2026-07-06
NCT03280888
Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)
Research · Centre Hospitalier Universitaire de Nice
CHU de Nice, Nice
Registry updated 2026-06-16
NCT07512882
Cohort of Patients With Chronic Myelomonocytic Leukemia
Research · Gustave Roussy, Cancer Campus, Grand Paris
Chu Amiens Picardie, Amiens · CHU Angers, Angers · Hôpital Privé Antony, Antony · AP-HP Hôpital Avicenne, Bobigny · Centre Hospitalier Sud Francilien, Corbeil-Essonnes · Chu Grenoble, Grenoble · AP-HP Hopital Bicetre, Le Kremlin-Bicêtre · Chru Lille - Hopital Claude Huriez, Lille · CHU Limoges, Limoges · CHU Nantes, Nantes · CHU Nice Hôpital l'Archet 1, Nice · Groupe Hospitalo-Universitaire Caremeau Institut de Cancérologie du Gard, Nîmes · AP-HP - Hôpital Saint-Antoine, Paris · AP-HP Hôpital Necker, Paris · AP-HP Hôpital Saint Louis, Paris · AP-HP Hôpital Cochin, Paris · CHU Bordeaux, Pessac · CHU Poitiers, Poitiers · Centre Henri Becquerel, Rouen · Centre Hospitalier Saint-Brieuc Hôpital Yves Le Foll, Saint-Brieuc · CHU Toulouse, Toulouse · CHU Tours, Tours · CHRU Nancy Brabois, Vandœuvre-lès-Nancy · Gustave Roussy, Villejuif
Registry updated 2026-05-19
NCT06514534
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Trial Treatment · Phase 2 · Novartis Pharmaceuticals
Bordeaux · Lille · Lyon · Nantes · Paris · Vandœuvre-lès-Nancy
Registry updated 2026-04-21
NCT05304377
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Trial Treatment · Phase 1 · Enliven Therapeutics
Centre Hospitalier Universitaire Amiens Picardie, Amiens Cedex 1 · Institut Bergonie, Bordeaux · Centre Hospitalier Universitaire De Lille, Lille Cedex · Centre Hospitalier Et Universitaire de Limoges, Limoges · Centre Leon Berard, Lyon
Registry updated 2026-04-01
NCT05969821
Clonal Hematopoiesis of Immunological Significance
Research · Assistance Publique - Hôpitaux de Paris
AP-HP, Service de médecine interne, Hôpital Saint Antoine, Paris
Registry updated 2026-03-23
NCT06082804
Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia
Trial Treatment · Centre Hospitalier Henri Duffaut - Avignon
Centre Hospitalier d'Avignon, Hôpital Henri Duffaut, Avignon
Registry updated 2026-03-04

All Chronic myeloid leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error